Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TScan Therapeutics, Inc. TCRX
$3.85
-$0.56 (-14.44%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
99973034.00000000
-
week52high
6.03
-
week52low
1.45
-
Revenue
13535000
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-2.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 04:00
Описание компании
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 10 мая 2022 г. |
| HC Wainwright & Co. | Buy | 16 дек 2021 г. | |
| Cowen & Co. | Outperform | 13 авг 2021 г. | |
| Morgan Stanley | Overweight | 10 авг 2021 г. | |
| Jefferies | Buy | 10 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Silver Brian M. | A | 32885 | 3158 | 28 дек 2022 г. |
| Silver Brian M. | A | 29727 | 2842 | 27 дек 2022 г. |
| MacBeath Gavin | A | 100000 | 100000 | 25 июл 2022 г. |
| Silver Brian M. | A | 220000 | 220000 | 25 июл 2022 г. |
| ZDRAVESKI ZORAN | A | 50000 | 50000 | 25 июл 2022 г. |
| Desmarais William | A | 30000 | 30000 | 25 июл 2022 г. |
| SOUTHWELL DAVID P | A | 100000 | 100000 | 25 июл 2022 г. |
| Barton Debora | A | 150000 | 150000 | 05 июл 2022 г. |
| Harel Ittai | A | 9146 | 9146 | 01 июн 2022 г. |
| Dorton Katina | A | 9146 | 9146 | 01 июн 2022 г. |
Новостная лента
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
PennyStocks
23 янв 2023 г. в 09:28
Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
TScan Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
22 сент 2022 г. в 07:00
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
GlobeNewsWire
07 сент 2022 г. в 07:00
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held at the Sheraton New York in New York, NY on Wednesday, September 14, 2022 at 12:55 p.m. ET.